Fair value · BioLineRx Ltd. (BLRX) · updated 2026-09-21 · from 20-F FY2025
BioLineRx trades at $2.54. We are not reading assumptions out of that price: this is a depositary receipt and we cannot show whether its per-share figures are stated per ADS or per ordinary share, so these methods are withheld rather than shown at a scale we cannot verify.
Everything below is unaffected: the filed statements, the filing they came from, and BLRX’s growth history are all as reported.
The filing behind these numbers
BioLineRx Ltd.- Revenue
- $1.2M
- Diluted EPS
- $0.00
- Free cash flow
- $-8.1M
- operating cash flow − capital expenditure
- Diluted shares
- 2.47B
- weighted average
20-F FY2025 · fiscal year ended 2025-12-31 · filed 2026-03-23 · accession 0001178913-26-001581
Open this filing on sec.govNeed BLRX data in your own agent or pipeline?
The valuation data behind this page — DCF fair value, margin of safety, PE vs industry, analyst estimates — is also available programmatically through the EvidInvest MCP server & financial data API for Claude, Cursor, or any MCP client and HTTP pipeline.